In a recent study comparing treatment outcomes in 55 patients with FH-deficient RCC, the analysis found that the treatment with ICIs in combination with tyrosine kinase inhibitor (TKI) may have a better clinical outcome compared to monotherapy [56]. This evidence concerns the gene FH and renal cell carcinoma.